Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
May 25, 2023 17:05 ET
|
Terns Pharmaceuticals, Inc.
- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose...
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
May 24, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
May 22, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
May 15, 2023 08:05 ET
|
Terns Pharmaceuticals, Inc.
- Top-line data from Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) in NASH expected in third quarter of 2023 - TERN-701 (allosteric BCR-ABL) Phase 1 trial for CML on track to...
Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference
May 09, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 27, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
- Announces key appointments in oncology R&D and business development functions - Cash and cash equivalents of $283 million expected to provide runway into 2026 FOSTER CITY, Calif., March ...
Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
March 27, 2023 08:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
March 02, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical...
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
February 02, 2023 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...